DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Other Current Assets
Current assets not reported separately, such as prepaid expenses.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 59.0% from a year ago
Other current assets stood at $1.03M at the end of Q1 FY2026, up 59.0% from a year earlier and up 114.6% from the prior quarter.
Context
- Other current assets amounted to 1.9% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +59.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 481K USD
- Year-over-year change
- +111.9%
- 4-year CAGR
- +18.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 481K | +111.9% |
| FY2024 | 2024-12-31 | 227K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 243K | — |
Other Current Assets vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 other current assets of $1.03M is the 6th highest of the 7 companies compared; the peer median is $3.55M.
- Its year-over-year change of +59.0% is the 2nd highest of 7, against a peer median of -26.7%.
- Other current assets amounts to 1.9% of total assets for DMAC, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BIOABioAge Labs, Inc. | Mar 2026 | $7.96M | +102.3% | +133.7% | 2.0% |
| Mar 2026 | $7.4M | +38.7% | +7.8% | 1.8% | |
| Mar 2026 | $5.31M | -33.0% | — | 1.5% | |
| Mar 2026 | $1.79M | -90.8% | +26.5% | 0.6% | |
| Mar 2026 | $1.09M | -20.4% | +94.6% | 1.7% | |
| Mar 2026 | $1.03M | +59.0% | — | 1.9% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding DMAC) | $3.55M | -26.7% | +60.5% | 1.6% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.